Nastech Pharmaceutical Company Inc. is an emerging pharmaceutical company dedicated to the development and commercialization of innovative drug delivery technologies and products.
Intranasal PYY 3-36 for Obesity. Description: PYY is a naturally occurring human hormone produced by specialized endocrine cells (L-cells) in the gut in proportion to the calorie ...
Get detailed information on NASTECH PHARM CO (NSTK) including quote performance, Real-Time ECN, technical chart analysis, key stats, insider transactions, and the latest company ...
Access the chart for ** SEE (NSTK) in line, bar or candlestick type. Customize the date range from 1 day, 5-day, 1-month, 3-month, 5-month or more. Perform chart performance ...
View printer-friendly version
View printer-friendly version
Co announced the issuance of a U.S. patent, No. 7,229,636, from the U.S. Patent and Trademark Office, titled Cyanocobalamin Low Viscosity Aqueous Formulations for Intranasal ...
Co announces the start of a Phase 2 clinical trial evaluating the co's PYY3-36 Nasal Spray in obese patients. The study will enroll approximately 500 obese patients for a six-month ...
Marketocracy has a mutual fund, stock quotes, stock picks, hot stocks, an investment newsletter, forums, stock research, trading by top investors, and a portfolio tracker. All of ...
Featured Posts. Bristol-Myers Security Breach Hits Untold Thousands; Massachusetts Gift Ban Is Removed From Bill; The Black Box Warning: Is The FDA Overreacting? Grassley Targets ...
Business News and Financial commentary, analysis, insight and entertainment from over 30 market pros who make, know, and trade them better than anyone.Latest Market update on Jeff ...
Pacific Northwest. Nastech. Nastech Pharmaceuticals said Tuesday it will reduce expenses by eliminating jobs, focusing on midstage development programs, and spinning off an ...
Nastech Pharmaceuticals: Biopharmaceuticals: June 30 % 2nd QTR: 2007: 2006: CHG: Profit ($12,367) ($560)-2,108: Per share (0.50) (0.03)-1,567: Revenue: 4,733: 11,238-57.9
Option update: Crocs (CROX) and Nastech Pharm (NSTK) volatility up on larger sell offs. Posted Nov 9th 2007 10:35AM by Paul Foster Filed under: Options, Crocs Inc (CROX)
Get detailed information on NASTECH PHARM CO (NSTK) including quote performance, Real-Time ECN, technical chart analysis, key stats, insider transactions, and the latest company ...
The company said Wednesday that Procter & Gamble Pharmaceuticals, a division of the consumer goods giant, had terminated its agreement to help Nastech develop and eventually market ...
Access the chart for NASTECH PHARM CO (NSTK) in line, bar or candlestick type. Customize the date range from 1 day, 5-day, 1-month, 3-month, 5-month or more. Perform chart ...
Article Abstract: The operations and management of Questcor Pharmaceuticals Inc of Union City, CA, are described in detail by CEO Charles J. Casamento.
SOURCE Nastech Pharmaceuticals Company Inc. -0- 10/13/2004 /CONTACT: investors, Stacie D. Byars, Director, Investor Relations of Nastech ...
NASTECH PHARM CO - NSTK - Summary, Chart, Share Price and further stock info ... Nastech Initiates New Corporate Direction with Name Change to MDRNA, Inc. and Appointment of J.
Nastech Pharmaceuticals Bothell, Washington PuRODI provided specification, procurement, and final installation services for a pit-mounted cage/rack washer ...
Competitors: Alteon, SONUS Pharmaceuticals, FOREST LABS INC, Alkermes, OSI Pharmaceuticals, Exelixis, Pozen, Enzon Pharmaceuticals InvestorGuide Research Links Stock: Nastech ...
Nastech awarded another grant to develop bird-flu drug Nastech Pharmaceutical Company has received a new $1.9m (?1.5m) research grant from the US National Institutes of
P&G in shock nasal spray exit Procter & Gamble (P&G) has this week terminated an agreement with Nastech to develop a nasally delivered version of
Nastech awarded another grant to develop bird-flu drug Nastech Pharmaceutical Company has received a new $1.9m (?1.5m) research grant from the US National Institutes of
NASTECH PHARM CO - NSTK - Summary, Chart, Share Price and further stock info ... Nastech Initiates New Corporate Direction with Name Change to MDRNA, Inc. and Appointment of J.
Nastech Pharm (NASDAQ: NSTK), a pharmaceutical company focused on molecular biology-based drug delivery technologies, closed at $7.09. James Cramer said on Nov. 1 when NSTK closed ...
NSTK - Nastech Pharmaceutical Company Inc. - Reuters Stock Buzz ... About Nastech Pharmaceutical Company Inc. - Answers.com Graphic_arrow1 Historical Prices - Yahoo Graphic_arrow1 ...
Senior Medical Director, Pharmacovigilance Takeda Pharmaceuticals North America - Deerfield, IL Chemical Development/cGMP Chemists AMRI - Albany, NY Business Development Director ...
Nastech acquires intellectual property targeting influenza ... Nastech Pharmaceutical Company Inc. said it has acquired RNAi therapeutics intellectual property that targets ...
|
|